Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s23166
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

Need for Streamlined Use of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2016English

Expert Committee on Novel DPP-4 Inhibitor TRADJENTA (Linagliptin) in Treatment of Type 2 Diabetesmellitus

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Emerging Treatments in Type 2 Diabetes: Focus on Canagliflozin

Therapeutics and Clinical Risk Management
2014English

DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2013English

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Systematic Literature Review of DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Renal Impairment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy